Antibiotic therapy and outcome from immune-checkpoint inhibitors

Pinato, David J., Gramenitskaya, Daria, Altmann, Daniel M., Boyton, Rosemary J., Mullish, Benjamin H., Marchesi, Julian R. ORCID: https://orcid.org/0000-0002-7994-5239 and Bower, Mark 2019. Antibiotic therapy and outcome from immune-checkpoint inhibitors. Journal for ImmunoTherapy of Cancer 7 (1) , 287. 10.1186/s40425-019-0775-x

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (547kB) | Preview

Abstract

Sensitivity to immune checkpoint inhibitor (ICPI) therapy is governed by a complex interplay of tumor and host-related determinants. Epidemiological studies have highlighted that exposure to antibiotic therapy influences the probability of response to ICPI and predict for shorter patient survival across malignancies. Whilst a number of studies have reproducibly documented the detrimental effect of broad-spectrum antibiotics, the immune-biologic mechanisms underlying the association with outcome are poorly understood. Perturbation of the gut microbiota, an increasingly well-characterized factor capable of influencing ICPI-mediated immune reconstitution, has been indicated as a putative mechanism to explain the adverse effects attributed to antibiotic exposure in the context of ICPI therapy. Prospective studies are required to validate antibiotic-mediated gut perturbations as a mechanism of ICPI refractoriness and guide the development of strategies to overcome this barrier to an effective delivery of anti-cancer immunotherapy.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
ISSN:	2051-1426
Date of First Compliant Deposit:	18 November 2019
Date of Acceptance:	9 October 2019
Last Modified:	08 May 2023 04:36
URI:	https://orca.cardiff.ac.uk/id/eprint/126920

Citation Data

Cited 77 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item